1 |
John, L. B., Howland, L. J., Flynn, J. K., West, A. C., Devaud, C., Duong, C. P., Stewart, T. J., Westwood, J. A., Guo, Z. S., Bartlett, D. L., Smyth, M. J., Kershaw, M. H. and Darcy, P. K. (2012) Oncolytic virus and anti-4-1BB combination therapy elicits strong anti-tumor immunity against established cancer. Cancer Res. 72, 1651-1660.
DOI
ScienceOn
|
2 |
Vinay, D. S. and Kwon, B. S. (2012) Immunotherapy of cancer by 4-1BB. Mol. Cancer Ther. 11, 1062-1070.
DOI
ScienceOn
|
3 |
Kwon, B. S. and Weissman, S. M. (1989) cDNA sequences of two inducible T-cell genes. Proc. Nat. Acad. Sci. U.S.A. 86, 1963-1967.
DOI
ScienceOn
|
4 |
Vinay, D. S. and Kwon, B. S. (2009) TNF superfamily: costimulation and clinical applications. Cell Biol. Int. 33, 453-465.
DOI
ScienceOn
|
5 |
Vinay, D. S. and Kwon, B. S. (2006) Genes, transcripts and proteins of CD137 receptor and ligand. In: CD137 pathway: immunology and diseases (Ed Chen L). Springer, New York, pp. 1-14.
|
6 |
Pollok, K. E., Kim, Y. J., Zhou, Z., Hurtado, J., Kim, K. K., Pickard, R. T. and Kwon, B. S. (1993) Inducible T cell antigen 4-1BB. Analysis of expression and function. J. Immunol. 150, 771-781.
|
7 |
Watts, T. H. (2005) TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23-68.
DOI
ScienceOn
|
8 |
Croft, M. (2003) Co-stimulatory members of TNFR family: keys to effective T-cell immunity. Nature Rev. Immunol. 3, 609-620.
DOI
ScienceOn
|
9 |
DeBenedette, M. A., Wen, T., Bachmann, M. F., Ohashi, P. S., Barber, B. H., Stocking K. L., Peschon, J. J. and Watts, T. H. (1999) Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J. Immunol. 163, 4833-4841.
|
10 |
Shuford, W. W., Klussman, K., Tritchler, D. D., Loo, D. T., Chalupny, J., Siadak, A. W., Brown, T. J., Emswiler, J., Raecho, H., Larsen, C. P., Pearson, T. C., Ledbetter, J. A., Aruffo, A. and Mittler, R. S. (1997) 4-1BB costimulatory signals preferentially induce T cell proliferation and lead to the amplification of in vivo cytotoxic T cell response. J. Exp. Med. 186, 47-55.
DOI
ScienceOn
|
11 |
Takahashi, C., Mittler, R. S. and Vella, A. T. (1999) 4-1BB is a bona-fide CD8 T cell survival signal. J. Immunol. 162, 5037-5040.
|
12 |
Kwon, B. S., Hurtado, J. C., Lee, Z. H., Kwack, K. B., Seo, S. K., Choi, B. K., Koller, B. H., Wolisi, G., Broxmeyer, H. E. and Vinay, D. S. (2002) Immune responses in 4-1BB (CD137)-deficient mice. J. Immunol. 168, 5483-5490.
DOI
|
13 |
Sun, Y., Lin, X., Chen, H. M., Wu, Q., Subudhi, S. K., Chen, L. and Fu, Y. X. (2002) Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J. Immunol. 168, 1457-1465.
DOI
|
14 |
Foell, J., Strahotin, S., O'Neil, S. P., McCausland, M. M., Suwyn, C., Haber, M., Chander, P. N., Bapat, A. S., Yan, X. J., Chiorazzi, N., Hoffmann, M. K. and Mittler, R. S. (2003) CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB NZWF1 mice. J. Clin. Invest. 111, 1505-1518.
DOI
|
15 |
Tirapu, I., Arina, A., Mazzolini, G., Duarte, M., Alfaro, C., Feijoo, E., Qian, C., Chen, L., Prieto, J. and Melero, I. (2004) Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int. J. Cancer 110, 51-60.
DOI
ScienceOn
|
16 |
Sun, Y., Chen, H. M., Subudhi, S. K., Chen, J., Koka, R., Chen, L. and Fu, Y. X. (2003) Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nature Med. 8, 1405-1413.
|
17 |
Agarwal, A. and Newell, K. A. (2008) The role of positive costimulatory molecules in transplantation and tolerance. Curr. Opin. Organ. Transplant 13, 366-372.
DOI
ScienceOn
|
18 |
Kim, J. A., Averbook, B. J., Chambers, K., Rothchild, K., Kjaergaard, J., Papay, R. and Shu, S. (2001) Divergent effects of 4-1BB antibodies on anti-tumor immunity and on tumor-reactive T-cell generation. Cancer Res. 61, 2031-2037.
|
19 |
Xu, D., Gu, P., Pan, P. Y., Li, Q., Sato, A. I. and Chen, S. H. (2004) NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int. J. Cancer 109, 499-506.
DOI
ScienceOn
|
20 |
Sabel, M. S., Conway, T. F., Chen, F. A. and Bankert, R. B. (2000) Monoclonal antibodies directed against the T cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenograft in severe combined immunodeficient mice. J. Immunother. 23, 362-369.
DOI
|
21 |
Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R. and Chen, L. (2002) Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109, 651-659.
DOI
|
22 |
Ju, S. A., Cheon, S. H., Park, S. M., Tam, N. Q., Kim, Y. M., An, W. G. and Kim, B. S. (2008) Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice. Int. J. Cancer 122, 2784-2790.
DOI
ScienceOn
|
23 |
May, K. F., Chen, L., Zheng, P. and Lui, Y. (2002) Anti-4-1BB monoclonal antibody enhances rejection of large burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res. 62, 3459-3465.
|
24 |
Miller, R. E., Jones, J., Le, T., Whitmore, J., Boiani, N., Gliniak, B. and Lynch, D. H. (2002) 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J. Immunol. 169, 1792-1800.
DOI
|
25 |
Murillo, O., Dubrot, J., Palazon, A., Arina, A., Azpilikueta, A., Alfaro, C., Solano, S., Ochoa, M. C., Berasain, C., Gabari, I., Perez-Gracia, J. L., Berraondo, P., Hervas-Stubbs, S. and Melero, I. (2009) In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur. J. Immunol. 39, 2424-2436.
DOI
ScienceOn
|
26 |
Zhu, B. Q., Ju, S. W. and Shu, Y. Q. (2009) CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4 (+) Th1 responses. Biomed. Pharmacother. 63, 509-516.
DOI
ScienceOn
|
27 |
June, C. H. (2007) Adoptive T cell therapy for cancer in clinic. J. Clin. Invest. 117, 1466-1476.
DOI
ScienceOn
|
28 |
Hernandez-Chacon, J. A., Li, Y., Wu, R. C., Bernatchez, C., Wang, Y., Weber, J. S., Hwu, P. and Radvanyi, L. G. (2011) Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J. Immunother. 34, 236-250.
DOI
|
29 |
Verneris, M. R., Arshi, A., Edinger, M., Kornacker, M., Natkunam, Y., Karami, M., Cao, Y. A., Marina, N., Contag, C. H. and Negrin, R. S. (2005) Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin. Cancer Res. 11, 4561-4570.
DOI
ScienceOn
|
30 |
Lu, P. H. and Negrin, R. S. (1994) A novel population of expanded human CD3+CD56+ cell derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 153, 1687-1696.
|
31 |
Hassan, R. and Ho, M. (2008) Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 44, 46-53.
DOI
ScienceOn
|
32 |
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., Carroll, R. G., Riley, J. L., Pastan, I. and June, C. H. (2009). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. U. S. A. 106, 3360-3365.
DOI
ScienceOn
|
33 |
Tammana, S., Huang, X., Wong, M., Milone, M. C., Ma, L., Levine, B. L., June, C. H., Wagner, J. E., Blazar, B. R. and Zhou, X. (2010). 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Human Gene Ther. 21, 75-86.
DOI
ScienceOn
|
34 |
Degang, S., Qunrui, Ye., Carmine, C., Mathilde, P., Li, P. W., Chunyan, J., Mariangela, F., Carl, H. J., George, C. S. and Daniel J. P. J. (2011) Improved survival provided by CD137 costimulatory signaling to folate receptor-redirected T cells results in tumor localization and eradication. Cancer Res. 171, 4617-4627.
|
35 |
Kocak, E., Lute, K., Chang, X., May, K. F., Exten, K. R., Zhang, H., Abdessalam, S. F., Lehman, A. M., Jarjoura, D., Zheng, P. and Liu, Y. (2006) Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 66, 7276-7284.
DOI
ScienceOn
|
36 |
Ito, F., Li, Q., Shreiner, A. B., Okuyama, R., Jure-Kunkel, M. N., Teitz-Tennenbaum, S. and Chang, A. E. (2004) Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 64, 8411-8419.
DOI
ScienceOn
|
37 |
Xu, D., Gu, P., Pan, P. Y., Li, Q., Sato, A. I. and Chen, S. H. (2004) NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int. J. Cancer 109, 499-506.
DOI
ScienceOn
|
38 |
Tirapu, I., Arina, A., Mazzolini, G., Duarte, M., Alfaro, C., Feijoo, E., Qian, C., Chen, L., Prieto, J. and Melero, I. (2004) Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int. J. Cancer 110, 51-60.
DOI
ScienceOn
|
39 |
Choi, B. K., Kim, Y. H., Kang, W. J., Lee, S. K., Kim, K. H. and Shin, S. M. (2007) Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res. 67, 8891-8899.
DOI
ScienceOn
|
40 |
Geiger, J. D., Wagner, P. D., Camerom, M. J., Shu, S. and Chang, A. E. (1993) Generation of T-cell reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J. Immunother. Emphasis Tumor Immunol. 13, 153-165.
DOI
|
41 |
Sun, Y., Blink, S. E., Chen, J. H. and Fu, Y. X. (2005) Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling. J. Immunol. 175, 884-890.
DOI
|
42 |
Kim, Y. H., Choi, B. K., Kang, W. J., Mittler, R. S. and Kwon, B. S. (2009) Mechanisms involved in synergistic anti-cancer effects of anti-4-1BB and cyclophosphamide therapy. Mol. Cancer Ther. 8, 469-478.
DOI
ScienceOn
|
43 |
Ju, S. A., Lee, S. C., Kwon, T. H., Heo, S. K., Park, S. M. and Park, S. M. (2005) Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumor-infiltrating lymphocytes. Immunol. Cell Biol. 83, 344-351.
DOI
ScienceOn
|
44 |
Choi, B. K., Kim, Y. H., Kim, C. H., Kim, M. S., Kim, K. H., Oh, H. S., Lee, M. J., Lee, D. K., Vinay, D. S. and Kwon, B. S. (2010) Peripheral 4-1BB signaling negatively regulates NK cell development through IFN- . J. Immunol. 185, 1404-1411.
DOI
ScienceOn
|
45 |
Middendorp, S., Xiao, Y., Song, J. Y., Peperzak, V., Krijger, P. H., Jacobs, H. and Borst, J. (2009) Mice deficient in CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma. Blood 114, 2280-2289.
DOI
ScienceOn
|
46 |
Zhang, N., Sadun, R. E., Arias, R. S., Flanagan, M. L., Sachsman, S. M., Nien, Y. C., Khawli, L. A., Hu, P. and Epstein, A. L. (2007) Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin. Cancer Res. 13, 2758-2767.
DOI
ScienceOn
|
47 |
Meseck, M., Huang, T., Ma, G., Wang, G., Chen, S. H. and Woo, S. L. C. (2011) A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer. J. Immunother. 34, 175-182.
|
48 |
Broll, K., Richter, G., Pauly, S., Hofstaedter, F. and Schwarz, H. (2001) CD137 expression in tumor vessel walls. High correlation with malignant tumors. Am. J. Clin. Pathol. 115, 543-549.
DOI
ScienceOn
|
49 |
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., June, C. H. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New. England. J. Med. 365, 725-733.
DOI
ScienceOn
|
50 |
Ho, W. T., Pang, W. L., Chong, S. M., Castella, A., Al-Salam, S., Tan, T. E., Moh, M. C., Koh, L. K., Gan, S. U., Cheng, C. K. and Schwarz, H. (2013) Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Cancer Res. 73, 652-661.
DOI
ScienceOn
|
51 |
Wan, Y. L., Zheng, S. S., Zhao, Z. C., Li, M. W., Jia, C. K. and Zhang, H. (2004) Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity. World J. Gasteroenterol. 10, 195-199.
DOI
|
52 |
Palma, C., Binaschi, M., Bigioni, M., Maggi, C. A. and Goso, C. (2004) CD137 and CD137 ligand constitutively expressed on human T and B leukemia cells signal proliferation and survival. Int. J. Cancer 108, 390-398.
DOI
ScienceOn
|
53 |
Anderson, M. W., Zhao, S., Freud, A. G., Czerwinski, D. K., Kohrt, H., Alizadeh, A. A., Houot, R., Azambuja, D., Biasoli, I., Morais, J. C., Spector, N., Molina-Kirsch, H. F., Warnke, R. A., Levy, R. and Natkunam, Y. (2012) CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am. J. Pathol. 181, 795-803.
DOI
ScienceOn
|
54 |
Shao, Z. and Schwarz, H. (2010) CD137 ligand, a member of the tumor necrosis factor family, regulated immune responses via reverse signal transduction. J. Leukobiol. 89, 21-29.
|
55 |
Chen, S. H., Pham-Nguyen, K. B., Martinet, O., Huang, Y., Yang, W., Thung, S. N., Chen, L., Mittler, R. and Woo, S. L. (2000) Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol. Ther. 2, 39-46.
DOI
ScienceOn
|
56 |
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellstrom, K. E., Mittler, R. S. and Chen, L. (1997) Monoclonal antibodies against the 4-1BB T-cell activating molecule eradicate established tumors. Nature Med. 3, 682-685.
DOI
ScienceOn
|
57 |
Carmeliet, P. and Jain, R. K. (2000) Angiogenesis in cancer and other diseases. Nature 407, 249-257.
DOI
ScienceOn
|
58 |
Sin, J. I., Kim, H., Ahn, E., Jeon, Y. H., Park, W. S., Lee, S. Y. and Kwon, B. (2013) Combined stimulation of TLR9 and 4-1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites. Cancer Lett. 3330, 190-199.
|
59 |
Shi, W. and Siemann, D. W. (2006) Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Res. 26, 3445-3453.
|
60 |
Schwarz, H., Tuckwell, J. and Lotz, M. (1983) A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family. Gene 134, 295-298.
|
61 |
Ko, E., Luo, W., Peng, L., Wang, X. and Ferrone, S. (2007) Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad anti angiogenic immunity. Cancer Res. 67, 7875-7884.
DOI
ScienceOn
|
62 |
Li, B., Lin, J., Vanroey, M., Jure-Kunkel, M. and Jooss, K. (2007) Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin. Immunol. 125, 76-87.
DOI
ScienceOn
|
63 |
Ye, Z., Hellstrom, I., Hayden-Ledbetter, M., Dahlin, A., Ledbetter, J. A. and Hellstrom, K. E. (2002) Gene therapy of cancer using single-chain Fv fragments specific for 4-1BB. Nature Med. 8, 343-348.
DOI
ScienceOn
|
64 |
Zhang, G. B., Dong, Q. M., Hou, J. Q., Ge, Y., Ju, S. G., Lu, B. F. and Zhang, X. G. (2007) Characterization and application of three novel monoclonal antibodies against human 4-1BB: distinct epitopes of human 4-1BB on lung tumor cells and immune cells. Tissue Antigens. 70, 470-479.
DOI
ScienceOn
|
65 |
Lindsedt, M., Johansson-Lindbom, B. and Borrebaeck, C. A. (2003) Expression of CD137 (4-1BB) on human follicular dendritic cells. Scand. J. Immunol. 57, 305-310.
DOI
ScienceOn
|
66 |
Vinay, D. S., Choi, B. K., Bae, J. S., Kim, W. Y., Gebhardt, B. M. and Kwon, B. S. (2004) CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J. Immunol. 173, 4218-4229.
DOI
|
67 |
Wu, H. C. and Li, P. C. (2008) Proteins expressed on tumor endothelial cells as potential targets for anti-angiogenic therapy. J. Cancer Mol. 4, 17-22.
|
68 |
Garni-Wagner, B. A., Lee, Z. H., Kim, Y. J., Wilde, C., Kang, C. Y. and Kwon, B. S. (1996) 4-1BB is expressed on CD45RAhiROhi transitional T cell in humans. Cell Immunol. 169, 91-98.
DOI
ScienceOn
|
69 |
Seo, S. K., Choi, J. H., Kim, Y. H., Kang, W. J., Park, H. Y., Suh, J. H., Choi, B. K., Vinay, D. S. and Kwon, B. S. (2004) 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nature Med. 10, 1088-1094.
DOI
ScienceOn
|
70 |
Palazon, A., Teijeira, A., Martinez-Forero, I., Hervas-Stubbs, S., Roncal, C., Penuelas, I., Dubrot, J., Morales-Kastresana, A., Perez-Gracia, J. L., Ochoa, M. C., Ochoa-Callejero, L., Martinez, A., Luque, A., Dinchuk, J., Rouzaut, A., Jure-Kunkel, M. and Melero, I. (2011) Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res. 71, 801-811.
DOI
|